Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and nonrheumatic disorders (Q41635870)

5 October 2017

1 reference

title

Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and nonrheumatic disorders (English)

1 reference

juvenile rheumatoid arthritis

5 October 2017

main subject

1 reference

1 reference

Singsen BH

1

1 reference

5 October 2017

Goldbach-Mansky R

series ordinal

2

1 reference

5 October 2017

publication date

1 November 1997

1 reference

Rheumatic Diseases Clinics of North America

5 October 2017

published in

1 reference

5 October 2017

volume

23

1 reference

5 October 2017

issue

4

1 reference

5 October 2017

page(s)

811-840

1 reference

Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics

5 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

High-performance liquid chromatography method for serum methotrexate levels in children with severe steroid-dependent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Malignancy following treatment of rheumatoid arthritis with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Methotrexate treatment every other week in patients with juvenile chronic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Methotrexate in rheumatoid arthritis--a limited sampling strategy for estimation of the area under the plasma concentration versus time curve.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Treatment of juvenile rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

l-folinic acid versus d,l-folinic acid in rescue of high-dose methotrexate therapy in children

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Methotrexate-associated appearance and rapid progression of rheumatoid nodules in systemic-onset juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Methotrexate therapy for juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Childhood dermatomyositis and polymyositis. Treatment with methotrexate and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Low-dose methotrexate therapy for childhood sarcoidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Methotrexate in juvenile rheumatoid arthritis. Do the benefits outweigh the risks?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Methotrexate treatment of Wegener granulomatosis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Effects of methotrexate on radiologic progression in juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Juvenile generalized pustular psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

The effect of food on the absorption of methotrexate sodium tablets in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Liver biopsy findings in patients with juvenile rheumatoid arthritis receiving long-term, weekly methotrexate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Methotrexate in childhood psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Methotrexate hepatotoxic effects in children with juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Methotrexate treatment of recalcitrant childhood dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Leucovorin versus folic acid in the treatment of methotrexate toxicity: comment on the article by Shiroky et al

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Alternative pharmacotherapies for steroid-dependent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Physician compliance and relapse rates of acute lymphoblastic leukemia in children

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Evaluation of therapeutic drug monitoring of methotrexate in saliva of children with rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Evaluation of response to methotrexate by a functional index in juvenile chronic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Serial measurements of soluble interleukin 2 receptor levels (sIL2-R) in children with juvenile rheumatoid arthritis treated with oral methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Wegener granulomatosis in children and adolescents: clinical presentation and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Dilated cardiomyopathy in juvenile chronic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Methotrexate bioavailability after oral and intramuscular administration in children

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970362-8

7 January 2021

10.1016/S0889-857X(05)70362-8

Identifiers

DOI

1 reference

5 October 2017

1 reference